BR112012009144B8 - rostafuroxina, método para a identificação de um indivíduo com melhor resposta à rostafuroxina e kit de partes para avaliar o tratamento de rostafuroxina para um indivíduo - Google Patents

rostafuroxina, método para a identificação de um indivíduo com melhor resposta à rostafuroxina e kit de partes para avaliar o tratamento de rostafuroxina para um indivíduo

Info

Publication number
BR112012009144B8
BR112012009144B8 BR112012009144A BR112012009144A BR112012009144B8 BR 112012009144 B8 BR112012009144 B8 BR 112012009144B8 BR 112012009144 A BR112012009144 A BR 112012009144A BR 112012009144 A BR112012009144 A BR 112012009144A BR 112012009144 B8 BR112012009144 B8 BR 112012009144B8
Authority
BR
Brazil
Prior art keywords
rostafuroxin
individual
treatment
systems
methods
Prior art date
Application number
BR112012009144A
Other languages
English (en)
Other versions
BR112012009144B1 (pt
BR112012009144A2 (pt
Inventor
Macciardi Fabio
Bianchi Giuseppe
Ferrari Patrizia
Original Assignee
Cvie Therapeutics Ltd
Rostaquo S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cvie Therapeutics Ltd, Rostaquo S P A filed Critical Cvie Therapeutics Ltd
Publication of BR112012009144A2 publication Critical patent/BR112012009144A2/pt
Publication of BR112012009144B1 publication Critical patent/BR112012009144B1/pt
Publication of BR112012009144B8 publication Critical patent/BR112012009144B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

métodos e sistemas para tratamento farmacogenômico de condições cardiovasculares. a presente invenção refere-se a sistemas e métodos que são baseados nos efeitos das variações genéticas das atividades biológicas associadas à rostafuroxina em um indivíduo. em particular, sistemas, métodos e composições são descritos neste documento que são baseados em uma influência identificada em uma resposta individual à rostafuroxina de um ou mais polimorfismos em uma região intergênica ou intragênica de um gene selecionado a partir do grupo consistindo em kcns3, thsd7a, fam46a, loc389970, hla-g, e ttc29, e/ou uma variação genética em desequilíbrio de ligação com este.
BR112012009144A 2009-10-19 2010-10-18 rostafuroxina, método para a identificação de um indivíduo com melhor resposta à rostafuroxina e kit de partes para avaliar o tratamento de rostafuroxina para um indivíduo BR112012009144B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25302009P 2009-10-19 2009-10-19
US61/253,020 2009-10-19
EP09177111.3 2009-11-25
EP09177111 2009-11-25
PCT/EP2010/065589 WO2011048033A2 (en) 2009-10-19 2010-10-18 Methods and systems for pharmacogenomic treatment of cardiovascular conditions

Publications (3)

Publication Number Publication Date
BR112012009144A2 BR112012009144A2 (pt) 2018-10-16
BR112012009144B1 BR112012009144B1 (pt) 2020-12-01
BR112012009144B8 true BR112012009144B8 (pt) 2021-05-25

Family

ID=41727473

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012009144A BR112012009144B8 (pt) 2009-10-19 2010-10-18 rostafuroxina, método para a identificação de um indivíduo com melhor resposta à rostafuroxina e kit de partes para avaliar o tratamento de rostafuroxina para um indivíduo

Country Status (23)

Country Link
US (1) US9408854B2 (pt)
EP (1) EP2490694B1 (pt)
JP (3) JP2013508329A (pt)
KR (3) KR20170121325A (pt)
CN (1) CN102695512B (pt)
AU (1) AU2010309921B2 (pt)
BR (1) BR112012009144B8 (pt)
CA (1) CA2777310C (pt)
DK (1) DK2490694T3 (pt)
EA (1) EA201270574A1 (pt)
ES (1) ES2551877T3 (pt)
HR (1) HRP20151185T1 (pt)
HU (1) HUE028075T2 (pt)
IL (1) IL219173A (pt)
ME (1) ME02347B (pt)
MX (1) MX2012004559A (pt)
PL (1) PL2490694T3 (pt)
PT (1) PT2490694E (pt)
RS (1) RS54416B1 (pt)
SG (1) SG10201406457VA (pt)
SI (1) SI2490694T1 (pt)
SM (1) SMT201500281B (pt)
WO (1) WO2011048033A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012066141A1 (en) * 2010-11-19 2012-05-24 Fondazione Centro San Raffaele Del Monte Tabor Markers for acute kidney injury and uses thereof
CN102940640A (zh) * 2012-12-06 2013-02-27 中国生命药物治疗有限公司 罗他夫辛在制备治疗基因缺陷型原发性高血压的药物中的用途
EP2937421B1 (en) * 2014-04-03 2018-10-24 Samsung Electronics Co., Ltd Biomarker for predicting effect of an anti-C-met antibody
KR102338678B1 (ko) * 2014-04-03 2021-12-13 삼성전자주식회사 항 c-Met 항체 효과 예측을 위한 바이오마커
WO2015183938A1 (en) 2014-05-29 2015-12-03 Geneticure Llc Improved therapeutic regimen for hypertension
US11761043B2 (en) 2014-05-29 2023-09-19 Geneticure Inc. Machine assay and analysis for selecting antihypertensive drugs
EP2977758A1 (en) * 2014-07-24 2016-01-27 Université De Nice Sophia Antipolis Methods and kits for monitoring membranous nephropathy
CN107447014A (zh) * 2015-01-21 2017-12-08 田小利 Thsd7a基因序列及表达改变检测及其在冠心病预测中的应用
CA3018186C (en) * 2016-03-29 2023-06-13 Regeneron Pharmaceuticals, Inc. Genetic variant-phenotype analysis system and methods of use
CN108728522A (zh) * 2018-06-11 2018-11-02 苏州艾达康医疗科技有限公司 药物基因组检测方法
US11337988B2 (en) 2018-09-27 2022-05-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of ouabain antagonists to inhibit viral infection
US11600375B2 (en) 2021-07-30 2023-03-07 Reviv Global Ltd Genetically personalized food recommendation systems and methods
US11894121B2 (en) 2021-08-06 2024-02-06 Reviv Global Ltd Prescriptive nutrition-based IV and IM infusion treatment formula creation systems and methods

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9001181D0 (en) 1990-01-18 1990-03-21 Imp Cancer Res Tech Genetic assay
DE4227616C2 (de) 1992-08-20 1995-04-13 Sigma Tau Ind Farmaceuti 17-(3-Furyl)-und 17-(4-Pyridazinyl)-5beta, 14beta-androstanderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammemsetzungen
US5632276A (en) 1995-01-27 1997-05-27 Eidelberg; David Markers for use in screening patients for nervous system dysfunction and a method and apparatus for using same
SE9501782D0 (sv) 1995-05-12 1995-05-12 Landstinget I Oestergoetland Method of predicting the therapeutic response of a drug against a malignant tumour
US6566332B2 (en) * 2000-01-14 2003-05-20 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
US20020132234A1 (en) * 2000-01-24 2002-09-19 Moskowitz David W. Nitric oxide synthase gene diagnostic polymorphisms
US6610489B2 (en) 2000-04-28 2003-08-26 Sangamo Biosciences, Inc. Pharmacogenomics and identification of drug targets by reconstruction of signal transduction pathways based on sequences of accessible regions
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US6867189B2 (en) * 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
US20040166491A1 (en) * 2001-08-09 2004-08-26 Henderson Lee A Vhl promoter diagnostic polymorphism
WO2003018745A2 (en) * 2001-08-21 2003-03-06 Glaxo Group Limited Method of screening for drug hypersensitivity reaction
IL161234A0 (en) * 2001-10-12 2004-09-27 Genset Sa Ngzipa, ngzipd, pgzipa and pgzipd polynucleotides and polypeptides and uses thereof
WO2003095485A2 (en) * 2002-05-10 2003-11-20 Serono Genetics Institute S.A. Krib polynucleotides and polypeptides and uses thereof in the treatment of metabolic disorders
EP1608782A2 (en) 2003-03-10 2005-12-28 Applera Corporation Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
EP2246444A1 (en) 2004-09-14 2010-11-03 The Regents of the University of Colorado, A Body Corporate Method for treatment with bucindolol based on genetic targeting
PT1951738E (pt) * 2005-11-25 2012-04-18 Rostaquo S P A Novas formas cristalinas de rostafuroxin
WO2009008412A1 (ja) * 2007-07-06 2009-01-15 National Institute Of Radiological Sciences 放射線治療後における泌尿器の晩期有害反応の発症予測用ｄｎａチップ、及びこれを用いた放射線治療後における泌尿器の晩期有害反応の発症予測方法
JP5476536B2 (ja) * 2007-10-03 2014-04-23 独立行政法人放射線医学総合研究所 乳癌の放射線治療による晩期副作用の発症を予測する方法
US20090221620A1 (en) * 2008-02-20 2009-09-03 Celera Corporation Gentic polymorphisms associated with stroke, methods of detection and uses thereof
JP2010106007A (ja) 2008-08-14 2010-05-13 Sony Corp 薬剤徐放剤、吸着剤、機能性食品、マスク及び吸着シート
JP5738267B2 (ja) * 2009-03-23 2015-06-24 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニＳｉｇｍａ−Ｔａｕ Ｉｎｄｕｓｔｒｉｅ Ｆａｒｍａｃｅｕｔｉｃｈｅ Ｒｉｕｎｉｔｅ Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ タンパク尿、糸球体硬化、及び腎不全の治療に有用な５−β，１４−β−アンドロスタン誘導体

Also Published As

Publication number Publication date
CA2777310A1 (en) 2011-04-28
DK2490694T3 (en) 2015-11-30
WO2011048033A2 (en) 2011-04-28
KR20170121325A (ko) 2017-11-01
PL2490694T3 (pl) 2016-02-29
JP2013508329A (ja) 2013-03-07
JP2014040418A (ja) 2014-03-06
PT2490694E (pt) 2015-12-02
WO2011048033A3 (en) 2011-07-14
HRP20151185T1 (hr) 2015-12-04
IL219173A (en) 2017-08-31
ME02347B (me) 2016-06-20
AU2010309921A1 (en) 2012-05-03
CA2777310C (en) 2018-08-28
KR20120093297A (ko) 2012-08-22
CN102695512B (zh) 2017-05-10
SG10201406457VA (en) 2014-11-27
KR20140060323A (ko) 2014-05-19
EA201270574A1 (ru) 2012-12-28
MX2012004559A (es) 2012-12-05
JP6130268B2 (ja) 2017-05-17
BR112012009144B1 (pt) 2020-12-01
BR112012009144A2 (pt) 2018-10-16
KR102053470B1 (ko) 2019-12-06
EP2490694B1 (en) 2015-09-16
EP2490694A2 (en) 2012-08-29
HUE028075T2 (en) 2016-11-28
ES2551877T3 (es) 2015-11-24
RS54416B1 (en) 2016-04-28
US9408854B2 (en) 2016-08-09
SI2490694T1 (sl) 2015-12-31
US20130018024A1 (en) 2013-01-17
AU2010309921B2 (en) 2017-04-13
SMT201500281B (it) 2016-01-08
IL219173A0 (en) 2012-06-28
JP2015128435A (ja) 2015-07-16
CN102695512A (zh) 2012-09-26

Similar Documents

Publication Publication Date Title
BR112012009144B8 (pt) rostafuroxina, método para a identificação de um indivíduo com melhor resposta à rostafuroxina e kit de partes para avaliar o tratamento de rostafuroxina para um indivíduo
CY1117574T1 (el) Αναλυση γονιδιωματικων κλασματων με χρηση των αριθμων πολυμορφισμων
BR122019002801B8 (pt) Método para selecionar uma planta de milho e método para identificar uma planta de milho transformada
BR112016003127A2 (pt) “composições e métodos para modular rna”
BR112018075099A2 (pt) novos loci genéticos associados a resistência a doença em soja
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
ATE502122T1 (de) Chemisch modifizierte oligonukleotidprimer zur nukleinsäureamplifikation
UA118649C2 (uk) ДВОЛАНЦЮГОВИЙ ЗАСІБ ДЛЯ PHKі ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ЕКСПРЕСІЇ ТРАНСТИРЕТИНУ (TTR)
GB201317477D0 (en) Methods, compositions and kits for determing the presence/absnece of a variant nucleic acid sequence
CY1121037T1 (el) Αντινοηματικα πολυνουκλεοτιδια για να διεγειρεται παραλειψη εξονιου και μεθοδοι θεραπειας δυστροφιων
BRPI1013410A2 (pt) processos de pcr para a caracterização da região não traduzida a 5' dos genes fmr1 e fmr2
EA201990924A1 (ru) Создание маиса, устойчивого к северной пятнистости листьев
WO2012170725A3 (en) Materials and method for identifying spinal muscular atrophy carriers
PE20141541A1 (es) Metodos y composiciones para producir arroz resistente a inhibidores de accasa
GB2456390A (en) Bipolar disorder treatments
MX2016005003A (es) Marcadores geneticos predictivos de respuesta al acetato de glatiramero.
WO2013056087A3 (en) Compositions and methods for treating and preventing coronary heart disease
BR112014028115A2 (pt) composições resistentes à circulação a frio contendo borracha e um copolímero em bloco
MX350967B (es) Marcadores geneticos para myb28.
BR112013022204A2 (pt) gene conferidor de resistência a oídio, planta de melão cucumis, sementes, partes de plantas, ou matéria de propagação de uma planta, sequência nucleotídica isolada, sequência de aminoácidos isolados, e utilização de um gene conferidor de resistência a oídio
BR112012010479A2 (pt) Metodo de seleção de uma planta de milho com resistencia aprimorada á ferrugem tropical, metodo de identificação de plantas de milho que exibem resistencia aprimorada á ferrugem tropical, planta de milho e metodo de identificação de uma ou mais variação alélicas associados a uma forma desejavel de uma caracteristica
WO2012056451A3 (en) Peripheral blood gene markers for early diagnosis of parkinson's disease
IN2014MN01989A (pt)
EP1989306A4 (en) TRANSCRIPTIONAL CONTROL SEQUENCES OF PLANT UF CELL
BR112015017788A2 (pt) Construto de dna, método para produzir uma planta, método de detecção da presença de uma molécula de ácido nucleico, par de iniciadores de polinucleotídio, evento de milho, método de detecção da presença do dna e kit para detectar ácidos nucleicos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25A Requested transfer of rights approved

Owner name: CVIE THERAPEUTICS LIMITED (TW)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/10/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF